AMRA has signed a new agreement to integrate its body composition analysis into Siemens Healthineers Digital Ecosystem for increased access to healthcare professionals and researchers. Intended to aid in disease prediction, AMRA’s body composition analysis is an automated method designed to convert a six-minute whole body MRI scan into 3D-volumetric fat and muscle measurements.
New US research has found that smoking while pregnant could be even worse for children with asthma than exposing them to secondhand smoke in childhood.
AstraZeneca today announced that the European Medicines Agency has accepted the Marketing Authorisation Variation forForxiga (dapagliflozin), a selective SGLT-2 inhibitor, for use as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D).
The global market for 3D printing of medical devices is estimated to touch $2.77 billion by 2015, according to a new study by market research and investment information firm Profshare Market Research.
A new prototype for wearable tremor suppression gloves has a team of Western University researchers believing real change is on the way for the more than 6 million people in the world afflicted by Parkinson's disease. For more information see the IDTechEx report on wearable technology.
Needle-free drug injection company PharmaJet is close to completing a $5 million fundraising round of financing that would fund the production of 5 million syringes to deliver the polio vaccine.
A new Norwegian study suggests that getting the right amount of vitamin D could substantially reduce an individual's risk of death.
With its worldwide impact and mounting death toll, the 2017-2018 influenza season shows that the viral disease isn’t just a fever and the sniffles, but rather a dangerous disease that can spread rapidly between people. That’s why a leading healthcare technology company is pushing forward with trials that can help doctors and medical staff easily identify the disease early in the process through a simple breath test.
Boston-based startup Pear Therapeutics will link with Novartis to develop prescription-strength digital interventions for schizophrenia and multiple sclerosis (MS).
Revamped Cas9 protein could work on more sites in the genome, and with fewer unwanted effects.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.